Facioscapulohumeral muscular dystrophy (MD), commonly known as FSHD or FSH, is a complex, inheritable muscle disease with an etiology that is rapidly becoming more el...

Oncology clinical trials are widely recognised as being amongst the most complex trials to design, set up, and deliver. Whilst there is good progress in finding optim...

In this paper, Robert Lins, MD, PhD, Respiratory Project Director at SGS, illustrates how respiratory drug development has, for years, been relying on the administrat...

In this Watch Pages item, Molly Fellin Spence, a medical and regulatory writer for the Cortellis database and AdComm Bulletin at Clarivate Analytics, discusses how th...

Electronic informed consent (eConsent) solutions have been introduced in recent years, representing a major advancement in improving information delivery to study par...

Adrenocortical carcinoma (ACC) is a rare cancer with an estimated incidence of 1 to 2 patients per million people annually. About 50%–70% of adrenal cancers are funct...

Pediatric legislation was introduced based on the American Academy of Pediatrics (AAP) concerns that children did not participate sufficiently in therapeutic progress...

Henry J. Riordan, Ph.D., Executive Vice President of Medical and Scientific Affairs and Global Lead for Neuroscience at Worldwide Clinical Trials, shares his views on...

A great number of willing patients, highly experienced researchers and EMA-compliant legislation make the CEE region an attractive research site destination. The data...

China has a large and vibrant ecosystem of patient advocacy groups and digital health networks that provides clinical trial sponsors with opportunities to engage and ...